We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

107 hedge funds and large institutions have $504M invested in Five Prime Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

127% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 11

43% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 28

19% more capital invested

Capital invested by funds: $425M → $504M (+$78.9M)

15% more funds holding

Funds holding: 93107 (+14)

100% less call options, than puts

Call options by funds: $2K | Put options by funds: $412K

Holders
107
Holders Change
+14
Holders Change %
+15.05%
% of All Funds
2.88%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
25
Increased
40
Reduced
28
Closed
11
Calls
$2K
Puts
$412K
Net Calls
-$410K
Net Calls Change
-$410K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$73.6M -$7.03M -315,451 -10%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$48.8M +$7.8M +350,208 +22%
State Street
3
State Street
Massachusetts
$35.8M +$7.26M +326,074 +29%
VVM
4
Versant Venture Management
California
$27.1M
EAM
5
Eventide Asset Management
Massachusetts
$23.8M +$2.64M +118,500 +14%
BFA
6
BlackRock Fund Advisors
California
$22.3M +$251K +11,247 +1%
GPP
7
Great Point Partners
Connecticut
$16.9M +$15.1M +678,595 New
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$15.4M -$40.1K -1,800 -0.3%
Vanguard Group
9
Vanguard Group
Pennsylvania
$14.3M +$982K +44,088 +8%
RI
10
RTW Investments
New York
$13.9M +$12.5M +560,437 New
BIT
11
BlackRock Institutional Trust
California
$12.6M +$1.68M +75,346 +17%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$11.9M -$12.1M -545,289 -53%
Millennium Management
13
Millennium Management
New York
$11.8M -$12.8M -576,056 -55%
PI
14
Putnam Investments
Massachusetts
$11.1M +$44.6K +2,000 +0.5%
GTC
15
Ghost Tree Capital
New York
$10.6M +$7.24M +325,000 +325%
QF
16
QVT Financial
New York
$10.1M
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
$8.48M +$7.6M +341,210 New
Lord, Abbett & Co
18
Lord, Abbett & Co
New Jersey
$6.85M +$6.15M +275,866 New
DCM
19
Driehaus Capital Management
Illinois
$6.01M -$70K -3,142 -1%
BI
20
BVF Inc
California
$5.98M -$5.84M -262,235 -52%
EAM
21
EverPoint Asset Management
Connecticut
$5.96M -$2.46M -110,384 -32%
AAM
22
Aureus Asset Management
Massachusetts
$5.94M +$2.17M +97,320 +69%
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$5.86M +$5.25M +235,652 +67,911%
Northern Trust
24
Northern Trust
Illinois
$5.84M +$404K +18,120 +8%
PA
25
Perceptive Advisors
New York
$5.57M

FPRX Hedge Fund Activity: Q2 2015 in Review

107 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2015, worth a combined $504M — up 19% from $425M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new FPRX positions and 11 closed out — a net gain of 14 holders — while 40 added to existing stakes and 28 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $15.1M. The largest seller was Millennium Management, cutting an estimated $12.8M.

  • 107 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2015, up from 93 in Q1 2015.
  • Funds reported $504M of Five Prime Therapeutics, Inc. stock for Q2 2015, up 19% quarter-over-quarter.
  • 25 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2015 and 11 closed out, a net change of +14 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q2 2015 was Great Point Partners, an estimated $15.1M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q2 2015 was Millennium Management, an estimated $12.8M sold.

Based on aggregated 13F filings for Q2 2015.